Roche Holding Ltd

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)